BioMedReports: There has been some talk about the upcoming opening of your new state-of-the-art facility. Can you tell us about that?
CEO Matthew L. Schissler: We always try to focus on three core goals and in 2010 we are opening our new state of the art laboratory. One of those three core goals is the diversification of revenue streams. Not only will we have our own organic growth engine, by processing and storing for our own company, but we recently entered into a letter of agreement to process and store for another very successful stem cell company. That’s
Adipose Stem Cell Heart Attack Trial Data Published in Journal of the American College of Cardiology; Cytori’s APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Function
Cytori Therapeutics announced today the publication of previously reported six-month outcomes from APOLLO, the Company’s European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction (heart attack or AMI), as Research Correspondence in the Journal of the American College of Cardiology. The APOLLO trial was a 14-patient, prospective, randomized, double-blind, placebo-controlled, feasibility trial (Phase I/IIA) evaluating autologous ADRCs extracted with the Company’s proprietary Celution® System for
A blood sample databank under the China Marrow Donor Program (CMDP), was officially established Monday at Zhongguancun of Beijing.
The new databank is now the largest for Chinese people in the world, according to Hong Junling, deputy head of CMDP management center.
The databank includes information such as the names and gender of nearly one million donors and information about to which ethnic groups the donors come from, Hong said.
It also covers such medical information as blood types, gene types and health status of the donors.
The CMDP, launched in 2001 by the Red Cross Society of China, aims to help millions
Stem cells could be responsible for some forms of aggressive thyroid tumors (ATC, anaplastic thyroid carcinoma). The discovery was made by a young group of biotechnologists, biologists, and doctors from the Endocrinology department of the General Hospital of the University of Palermo. In the study, published in Plos One, the researchers described a subset of tumor stem cells that were able to proliferate continuously and may be responsible for uncontrolled tumor growth. These cells are resistant to chemotherapy and explain why ATC is so highly fatal in such a short period of time. The
A team of researchers from UCL has won a £500,000 grant to develop a synthetic artery that mimics a natural artery – and could revolutionise the treatment of coronary heart disease.
Professor Alexander Seifalian (UCL Surgery and Interventional Science) and Professor George Hamilton (UCL Surgery and Interventional Science & Royal Free Hospital) and their team will use the Wellcome Trust grant to take their work from the laboratory to a pre-clinical trial.
The team has been developing a new nanomaterial with mechanical properties similar to that of human arteries.
The nanomaterial’s inner surface has been modified to attract stem cells from blood